Spectra Industries Ltd
F&OSPECTRABSE
₹3.61▼ -0.19 (-5.00%)
Whole company worth₹866 Cr
Price for ₹1 of profit₹0.1
1-year range₹3 – ₹6
The short version
A shrinking, loss-making business.
What Spectra does
Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs).
Worked out from Spectra's own filed results and exchange data, in plain words. Where a finance term matters, we say what it means.
01What does it do?
Spectra is a small-sized company in pharmaceuticals & biotechnology.
Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market. It is the largest pharmaceutical company in India.
- Whole company is worth
- ₹866 crore
- Run by
- Dilip Shantilal Shanghvi
- Employees
- 43,000
- Shareholders
- 7.1 lakh people
- Listed since
- 1994
A small company by stock-market value — these tend to move more sharply.
02Is it growing?
Sales fell 100% last year.
There is not enough history yet to judge Spectra's growth over several years.
Point at a bar for exact figures · amounts in ₹ crore
03Does it make money?
Out of every ₹100 it sells, it keeps ₹21 as profit.
Here is where the money from Spectra's sales went in FY25, the latest full year it has reported.
₹74
₹21
- ₹74Costs of running the businessstaff, rent, marketing, power and everything else
- ₹0.4Interest on its loansthe cost of borrowed money
- ₹4.9Wear and tearmachines, stores and buildings losing value over time
- ₹21Profit it keepswhat is left for the company's owners
On the money its owners have put in
It earns ₹16 a year on every ₹100 its owners have invested.
Bank FD ~₹6–7
₹16
₹0₹10₹20₹30₹40
That figure is called return on equity (ROE). Between ₹12 and ₹20 is a respectable return. For comparison, a bank fixed deposit pays roughly ₹6–7.
Does the profit turn into cash?
For every ₹100 of profit it reported, ₹188 actually came in as cash.
Profit it reported₹20,572 Cr
Cash its business brought in₹38,626 Cr
Over the last 3 years: ₹20,572 crore of profit and ₹38,626 crore of cash from its day-to-day business. Profit that shows up as cash is the most believable kind.
04Is the price high or low?
You pay ₹0.1 for every ₹1 of profit it makes in a year.
This is the P/E ratio: share price divided by a year's profit per share. A P/E of 0.1 means buyers are paying for about 0.1 years of today's profit up front.
The share price over the past year
It is 44% below its highest price of the past year and 11% above its lowest.
05Who owns it?
Its founders and parent group own 54 of every 100 shares — they control the company.
If the company were split into 100 equal shares, this is who would hold them. Last quarter, foreign investors cut their stake by 1.4 percentage points. 7.1 lakh people and institutions hold its shares.
As filed for the quarter ending 30 Jun 2026. Arrows show the change since the quarter before, in percentage points.
06What is going well, and what to watch
One thing going well, four things worth watching.
Picked out of the numbers above by fixed rules — the same rules for every company — so nothing here is somebody's opinion.
Going well
- Has almost no debt — it is not at the mercy of lenders.
Worth watching
- Sales fell 100% in the latest financial year.
- Lost ₹3.3 crore in its last financial year.
- Thinly traded — only about ₹1 lakh of shares change hands a day, so buying or selling can move the price.
- The share price is 44% below its high of the past year.
07What happened lately?
Its latest quarter.
Apr–Jun 2026 is the most recent quarter it has reported. Each figure is compared with the same three months a year earlier, because many businesses sell more in some seasons than others.
Sales
₹15,300 Cr
Profit
₹2,901 Cr
No notable developments in the last few weeks.
Advanced view
Every number, every table, the full chart.
Ten years of statements, quarterly results, peers side by side, technical indicators, analyst estimates, bulk deals and filings.
Ask DoXy
Still have a question about Spectra?
This page describes Spectra using its reported figures and exchange data. It is for information only and is not investment advice or a recommendation to buy, sell or hold. DocStoX is not a SEBI-registered investment adviser or research analyst.
Spectra Industries Ltd (SPECTRA): company summary
The company's annual revenue rose 8.4% to ₹52,578 crore, while annual net profit increased 14.1% to ₹10,965 crore.
Spectra Industries Ltd (SPECTRA) is a micro-cap Healthcare company valued at ₹866 crore operating in Pharmaceuticals & Biotechnology on the NSE and BSE.
- Recent price move
- Spectra Industries Ltd last traded at ₹3.61, sharply down 5.00% on the day.
- Recent developments
- On 2026-06-30, the company reported a net loss of ₹3 crore in its latest financial year, despite higher revenue and profit in the latest quarter. The company's promoter holding remained at 54.48% as of 2026-06-30, with foreign institutional holding at 14.53% and domestic institutional holding at 22.07%.
- Financial performance
- The company's annual revenue rose 8.4% to ₹52,578 crore, while annual net profit increased 14.1% to ₹10,965 crore. In the latest quarter, revenue grew 10.5% to ₹15,300 crore, and net profit rose 26.5% to ₹2,901 crore, outpacing the year-ago quarter's ₹13,851 crore and ₹2,293 crore respectively.
- Valuation multiples
- The stock trades at 0.1 times earnings, a discount to the Healthcare median of 32.0, -0.05 times book value.
- Things to watch
- The company reported a net loss of ₹3 crore in its latest financial year, despite higher revenue and profit in the latest quarter. The stock is 41.3% below its 52-week high, and the net profit margin, though up 1.0 percentage points to 20.9%, is still lower than the prior year's 19.8%.
- Where it stands
- The company's latest quarter showed strong growth in both revenue and net profit, but it reported a net loss in its latest financial year. The stock is significantly below its 52-week high, and the net profit margin, while up, remains lower than the prior year. The company's promoter holding remains at 54.48% as of 2026-06-30.
Summarised by DocStoX's model on 2026-10-18 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.
More Healthcare stocks · Pharmaceuticals & Biotechnology
Explore Spectra Industries Ltd’s valuation
Free deep-dive tools · no sign-up
Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.
Spectra Industries Ltd peers in Healthcare
Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.
Sun Pharmaceutical Industries LimitedDivi's Laboratories LimitedTorrent Pharmaceuticals LimitedLaurus Labs LimitedZydus Lifesciences LimitedApollo Hospitals Enterprise LimitedCipla LimitedDr. Reddy's Laboratories LimitedMankind Pharma LimitedAurobindo Pharma LimitedLupin LimitedManipal Health Enterprises Limited
Compare Spectra Industries Ltd with peers
Spectra Industries Ltd vs Sun Pharmaceutical Industries LimitedSpectra Industries Ltd vs Divi's Laboratories LimitedSpectra Industries Ltd vs Torrent Pharmaceuticals LimitedSpectra Industries Ltd vs Laurus Labs LimitedSpectra Industries Ltd vs Zydus Lifesciences LimitedSpectra Industries Ltd vs Apollo Hospitals Enterprise Limited
Related tools & concepts
Value Spectra Industries Ltd with the ratios and calculators DocStoX uses in its analysis.
P/E RatioPrice to earningsReturn on Equity (ROE)ProfitabilityROCECapital efficiencyDebt to EquityLeverageP/B RatioPrice to bookNet Profit MarginBottom-line efficiencyDCF / Intrinsic ValueEstimate fair valueCAGR CalculatorAnnualised returnDividend YieldIncome on pricePosition SizeRisk-based sizingBrokerage CalculatorCharges on a tradeSIP CalculatorSystematic investing